NICE stiff-arms Alexion's $552K Strensiq; Mylan falls under DOJ scrutiny for generic prices;

> The cost-effectiveness watchdogs at the U.K.'s National Institute for Health and Care Excellence said "no go" to Alexion's ($ALXN) $552,000 price on its new rare disease med Strensiq. Report

> The U.S. Justice Department issued a subpoena to Mylan ($MYL), the most recent of a group of drugmakers to come under scrutiny for prices of their generic meds. Report

> Biofrontera won approval in Switzerland for Ameluz, its new skin cancer med; the drug is also under review at the FDA. Release (PDF)

And Finally... Stallergenes is recalling allergy immunotherapies shipped from a plant in Antony, France, after August 13. Report

Suggested Articles

Eli Lilly bought full-page ads in more than a dozen newspapers in the U.S. to let people with diabetes who use Lilly drugs to know help is available.

Only months after a game-changing new approval for Vascepa, Amarin has lost a key fight over its patents—and now it's scrambling to respond.

Move over, Roche. There’s a new small cell lung cancer therapy on the scene, and it belongs to AstraZeneca.